Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saracatinib neuroimaging in alcoholism risk
NCT02262026Phase 1Completed
- Sponsor
- Yale University
- Start
- Nov 2014
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of saracatinib in alcohol use disorder (AUD) (12 arms), sponsored by Yale University. Primary endpoint: BOLD activation during A1 phase. Started Nov 2014; status: completed.
02
Drugs
saracatinib
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT02262026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02262026.